Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2026 Jun 19;17:1902412. doi: 10.3389/fimmu.2026.1902412

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

Nabil E Omar 1,2,*, Shereen Elazzazy 1,3, Anas Hamad 1,3, Mohamed Omar Saad 4, Aya Alasmar 1, Sahar M Nasser 1, Maria Benkhadra 1, Hebatalla M Afifi 1, Farah I Jibril 1, Rawan A Dawoud 1, Mohamed S Hamid 5, Afnan Alnajjar 1, Arwa O Sahal 1, Amaal Gulied 1, Hazem Elewa 3,*
PMCID: PMC13329446  PMID: 42404898

In the Acknowledgements and the Funding statement, this sentence was erroneously omitted: “The publication of this article was funded by the Qatar National Library.”

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES